Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
98.20    -0.80 (-0.81%)
Bid:
98.20
Ask:
99.00
Spread: 0.80 (0.815%)
Market Cap: £597.25m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Proposed changes to expense arrangements

24 Nov 2015 10:40

BACIT LIMITED - Proposed changes to expense arrangements

BACIT LIMITED - Proposed changes to expense arrangements

PR Newswire

London, November 24

BACIT LIMITED(a closed-ended investment company incorporated in Guernseywith registration number 55514)

(the "Company")

24 November 2015

Proposed changes to expense arrangements

The Company announces a proposed change to the basis on which the operating expenses of BACIT (UK) Limited, the Company’s investment manager (the “Investment Manager”), are paid with effect from 1 January 2016. The proposed change is subject to shareholder approval. 

The key features of the Company’s investment policy — that it will invest in underlying funds on a “gross return” basis, that it will invest up to one per cent. per annum of its net asset value in drug development projects and that it will donate one per cent. per annum of its net asset value to charities including the Institute for Cancer Research (“ICR”) — will remain unchanged. Both the ICR and the managers of the underlying funds in which the Company currently invests are supportive of the proposed change. 

To date, neither the Investment Manager nor the BACIT investment management team have received a fee from the Company for their investment management services. Under the proposed arrangements, the personnel costs and operating expenses of the investment management function will be covered by a new fee payable by the Company to the Investment Manager equal to 0.19% per annum of the Company’s net asset value. It is not envisaged that the Investment Manager should make a meaningful profit from the fee. Notwithstanding the proposed changes to the expense arrangements Tom Henderson will continue to provide his services as a director of the Company and as CEO of the Investment Manager free of charge. 

A circular, including a notice of an extraordinary general meeting of the Company to approve the proposed changes to the expense arrangements intended to be held at 9.30 a.m. on 11 December 2015 at the offices of Northern Trust International Fund Administration Services (Guernsey) Limited, Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 3QL will be sent to shareholders shortly. 

A copy of the circular, when published, be available on the Company's website at http://www.bacitltd.com. The Circular will also be submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/nsm.

Enquiries:

Northern Trust International Fund Administration Services (Guernsey) Limited

Tel: +44 (0) 1481 745368

Date   Source Headline
4th Jun 20197:00 amRNSAppointment of Chair-Designate and NED
20th May 20197:00 amRNSSyncona founds Quell with £35m Series A Financing
14th May 201912:00 pmRNSAutolus reports Q1 2019 Financial Results
7th May 20197:00 amRNSBED announces initial clinical experience of PSMA
16th Apr 20197:00 amRNSAutolus announces closing of public offering
11th Apr 20197:09 amRNSAutolus announces pricing of public offering
11th Apr 20197:00 amRNSCreation of leading retinal gene therapy platform
9th Apr 20197:00 amRNSAutolus announces launch of proposed offering
1st Apr 20196:14 pmRNSAutolus presents initial AUTO1 adult ALL data
27th Mar 201911:12 amRNSDirector/PDMR Shareholding
26th Mar 201910:18 amRNSAutolus hosts R&D day and updates on AUTO3
20th Mar 20194:27 pmRNSDirector/PDMRs Shareholding
19th Mar 20195:48 pmRNSStandard form for notification of major holdings
19th Mar 20194:44 pmRNSDirectors/PDMR Shareholdings
18th Mar 20194:15 pmRNSNotification of Major Holdings
13th Mar 20194:55 pmRNSResults of Placing in Syncona Limited
13th Mar 20197:00 amRNSProposed Placing in Syncona Limited
12th Mar 20197:00 amRNSUpdate on management of strategic capital pool
4th Mar 20197:11 amRNSNightstar agreement to be acquired by Biogen
26th Feb 20197:00 amRNSSyncona leads CHF 35 million financing in Anaveon
19th Feb 201911:52 amRNSAutolus announces Results from CARPALL Trial
13th Feb 20197:00 amRNSQuarterly Update
16th Jan 20197:00 amRNSAppointment of Joint Corporate Broker
17th Dec 201812:38 pmRNSChange of Registered Office - Released in Error
17th Dec 201811:47 amRNSChange of Registered Office
4th Dec 20187:00 amRNSFreeline presents data at the ASH Annual Meeting
3rd Dec 20187:00 amRNSAutolus announces update on AUTO4 and AUTO5
3rd Dec 20187:00 amRNSAutolus presents AUTO3 data at ASH Annual Meeting
26th Nov 20189:57 amRNSAutolus publishes Annual Report
21st Nov 20187:10 amRNSInterim Results
13th Nov 20187:00 amRNSNightstar reports Q3 2018 financial results
1st Nov 20181:40 pmRNSAutolus Therapeutics to Present New Data at ASH
1st Nov 20181:36 pmRNSFreeline releases initial data for FLT180a
1st Nov 20187:00 amRNSDirector Information
30th Oct 201811:24 amRNSResult of Extraordinary General Meeting
4th Oct 20187:00 amRNSPublication of EGM Circular
3rd Oct 20187:00 amRNSNightstar closes public offering
28th Sep 20187:00 amRNSNightstar announces pricing of public offering
24th Sep 20187:00 amRNSNightstar reports positive proof of concept data
3rd Sep 201811:22 amRNSChange of Administrator and Depositary
31st Aug 20184:08 pmPRNTotal Voting Rights
13th Aug 201812:39 pmPRNIssue of shares pursuant to the Long Term Incentive Plan
13th Aug 201811:11 amPRNNightstar reports Q2 2018 financial results
9th Aug 20187:00 amPRNSyncona Limited Quarterly Update
2nd Aug 20184:49 pmPRNPDMR Dealing
31st Jul 20182:21 pmPRNResults of AGM
31st Jul 20187:00 amPRNTotal Voting Rights
30th Jul 201812:45 pmPRNDirectors Dealings
25th Jul 20187:00 amPRNIssue of shares pursuant to the 2018 dividend
29th Jun 201812:45 pmPRN2018 Dividend Scrip Reference Price

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.